Orexo Announces FDA Acceptance of Investigational New Drug (IND) Application for OX640 for the Treatment of Anaphylaxis
Uppsala, Sweden — September 14th 2026 — Orexo AB (publ.) (STO:ORX) (OTCQX:ORXOY) today announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OX640, a nasally administered powder formulation of epinephrine intended for the emergenc…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.